Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers.
Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers.
复制标题
DOI：
10.1038/s41467-021-24579-7
复制
发表时间：
2021-07-29
影响因子：
16.6
通讯作者：
Malavige GN
中科院分区：
文献类型：
--
作者：
Jeewandara C;Kamaladasa A;Pushpakumara PD;Jayathilaka D;Aberathna IS;Danasekara DRSR;Guruge D;Ranasinghe T;Dayarathna S;Pathmanathan T;Somathilake G;Deshan Madhusanka PA;Ramu ST;Pramanayagam Jayadas TT;Kuruppu H;Wijesinghe A;Thashmi Nimasha HM;Milroy D;Nandasena AA;Nilanka Sanjeewani PKG;Wijayamuni R;Samaraweera S;Schimanski L;Tan TK;Dong T;Ogg GS;Townsend A;Malavige GN
几种COVID-19疫苗已获得紧急批准。在这里，我们在一组卫生保健工作者（HCWs） （629 naïve和26先前感染）中评估了单剂量AZD1222疫苗一个月后的免疫原性。93.4%的naïve卫生保健工作者血清转化，不分年龄和性别。在亚队列中进行受体结合域（RBD）抗体血凝试验、替代中和试验（sVNT）和体外IFNγ ELISpot测定。在67/69例（97.1%）naïve HCWs中检测到ACE2阻断抗体（sVNT检测）。对野生型RBD的抗体水平高于对B.1.1.7 RBD的抗体水平，对B.1.351的抗体滴度很低。30.8% ~ 61.7%的naïve HCWs患者有体外T细胞应答。先前感染的HCWs， ACE2阻断抗体和针对B.1.1.7和B.1.351变体的RBD抗体显著升高（p < 0.0001）。这项研究表明，一剂疫苗后血清转化率高，但也表明，一剂疫苗可能不足以防止新出现的变异。在这里，作者在一大群医护人员中表明，一剂AZD1222疫苗的血清转化率为92.9%，无论年龄和性别如何，并且导致对野生型SARS-CoV-2的高抗体滴度，但对B.1.351变体的抗体滴度较低。
Several COVID-19 vaccines have received emergency approval. Here we assess the immunogenicity of a single dose of the AZD1222 vaccine, at one month, in a cohort of health care workers (HCWs) (629 naïve and 26 previously infected). 93.4% of naïve HCWs seroconverted, irrespective of age and gender. Haemagglutination test for antibodies to the receptor binding domain (RBD), surrogate neutralization assay (sVNT) and ex vivo IFNγ ELISpot assays were carried out in a sub-cohort. ACE2 blocking antibodies (measured by sVNT) were detected in 67/69 (97.1%) of naïve HCWs. Antibody levels to the RBD of the wild-type virus were higher than to RBD of B.1.1.7, and titres to B.1.351 were very low. Ex vivo T cell responses were observed in 30.8% to 61.7% in naïve HCWs. Previously infected HCWs, developed significantly higher (p < 0.0001) ACE2 blocking antibodies and antibodies to the RBD for the variants B.1.1.7 and B.1.351. This study shows high seroconversion after one vaccine dose, but also suggests that one vaccine dose may be insufficient to protect against emerging variants. Here the authors show in a large cohort of healthcare workers that one dose of the AZD1222 vaccine seroconverts 92.9% of vaccinees, irrespective of age and gender, and results in high antibody titers to wild-type SARS-CoV-2 but only low titers to the B.1.351 variant.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
DOI：
10.1016/s0140-6736(21)00677-2
发表时间：
2021-05-01
期刊：
Lancet (London, England)
影响因子：
--
作者：
Vasileiou E;Simpson CR;Shi T;Kerr S;Agrawal U;Akbari A;Bedston S;Beggs J;Bradley D;Chuter A;de Lusignan S;Docherty AB;Ford D;Hobbs FR;Joy M;Katikireddi SV;Marple J;McCowan C;McGagh D;McMenamin J;Moore E;Murray JL;Pan J;Ritchie L;Shah SA;Stock S;Torabi F;Tsang RS;Wood R;Woolhouse M;Robertson C;Sheikh A
通讯作者：
Sheikh A
影响因子：
4.6
作者：
Jeewandara C;Jayathilaka D;Gomes L;Wijewickrama A;Narangoda E;Idampitiya D;Guruge D;Wijayamuni R;Manilgama S;Ogg GS;Tan CW;Wang LF;Malavige GN
通讯作者：
Malavige GN
DOI：
10.1136/bmj.n579
发表时间：
2021-03-09
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Challen R;Brooks-Pollock E;Read JM;Dyson L;Tsaneva-Atanasova K;Danon L
通讯作者：
Danon L
影响因子：
46.9
作者：
Tan, Chee Wah;Chia, Wan Ni;Wang, Lin-Fa
通讯作者：
Wang, Lin-Fa